{"created":"2023-05-15T09:47:27.704453+00:00","id":9548,"links":{},"metadata":{"_buckets":{"deposit":"271e9811-94e7-4e79-b2d0-eb2ba8998d8f"},"_deposit":{"created_by":11,"id":"9548","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"9548"},"status":"published"},"_oai":{"id":"oai:kagawa-u.repo.nii.ac.jp:00009548","sets":["13:40"]},"author_link":["3482"],"item_10006_alternative_title_1":{"attribute_name":"その他（別言語等）のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"切除不能進行・再発大腸癌に対する一次治療としてのカペシタビン、イリノテカン、オキサリプラチン、ベバシズマブ併用療法 : QUATTRO-II試験の安全性導入パート結果","subitem_alternative_title_language":"ja"}]},"item_10006_date_granted_11":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2022-03-24"}]},"item_10006_degree_grantor_9":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"香川大学"},{"subitem_degreegrantor_language":"en","subitem_degreegrantor_name":"Kagawa University"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"16201","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10006_degree_name_8":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_10006_description_7":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: FOLFOXIRI plus bevacizumab is the first-line treatment for metastatic colorectal cancer (mCRC) but demonstrates high neutropenia incidence among Asian patients. Hence, we conducted the randomized phase II QUATTRO-II study (ClinicalTrials.gov identifier: NCT04097444; Japan Registry of Clinical Trials identifier: jRTCs041190072) to evaluate the safety and efficacy of capecitabine, oxaliplatin, and irinotecan (CAPOXIRI) combination plus bevacizumab versus FOLFOXIRI plus bevacizumab, expecting a lower incidence of neutropenia without compromising the efficacy.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Methods: We investigated the recommended doses (RD) of oxaliplatin and irinotecan as a safety lead-in portion of Step 1 before initiating the randomized portion as Step 2. Four dose levels of CAPOXIRI (fixed dose of capecitabine, 1600 mg/m2; escalated/de-escalated doses of oxaliplatin and irinotecan) plus bevacizumab (7.5 mg/kg) were investigated in a 3 + 3 manner. A dose level of ≤ 2/6 of dose-limiting toxicity (DLT) cases was expected as the RD.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Results: In Step 1, we included nine patients (three and six in levels 0 and + 1, respectively). Level 0 (irinotecan, 200 mg/m2; oxaliplatin, 100 mg/m2) did not demonstrate DLTs. In level + 1 (irinotecan, 200 mg/m2; oxaliplatin, 130 mg/m2), although one patient experienced grade 4 febrile neutropenia, no further safety concerns were observed. As a preliminary efficacy result, the objective response rate in all nine patients was 89 % (100 and 83 % in levels 0 and + 1, respectively). ","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Conclusions: The RD of CAPOXIRI plus bevacizumab was 200, 130, and 1600 mg/m2 for irinotecan, oxaliplatin, and capecitabine, respectively, and 7.5 mg/kg for bevacizumab. The randomized portion is still ongoing.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10006_dissertation_number_12":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第797号"}]},"item_10006_relation_15":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s10637-021-01125-2","subitem_relation_type_select":"DOI"}},{"subitem_relation_type":"hasVersion","subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8541955/","subitem_relation_type_select":"URI"}}]},"item_10006_relation_22":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"34019214","subitem_relation_type_select":"PMID"}}]},"item_10006_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © 2021, The Author(s).","subitem_rights_language":"en"},{"subitem_rights":"Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.","subitem_rights_language":"en"}]},"item_10006_version_type_18":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_fa2ee174bc00049f","subitem_version_type":"P"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小谷, 大輔","creatorNameLang":"ja"},{"creatorName":"コタニ, ダイスケ","creatorNameLang":"ja-Kana"},{"creatorName":"Kotani, Daisuke","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-04-20"}],"displaytype":"detail","filename":"Med_A797.pdf","filesize":[{"value":"366.4 kB"}],"format":"application/pdf","licensetype":"license_6","mimetype":"application/pdf","url":{"label":"本文","objectType":"fulltext","url":"https://kagawa-u.repo.nii.ac.jp/record/9548/files/Med_A797.pdf"},"version_id":"90f03896-74d9-45df-9c6a-361cafa68b2f"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-04-20"}],"displaytype":"detail","filename":"Med_A797_abstract.pdf","filesize":[{"value":"63.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"内容の要旨","objectType":"abstract","url":"https://kagawa-u.repo.nii.ac.jp/record/9548/files/Med_A797_abstract.pdf"},"version_id":"a497816a-d930-4f47-93dd-742bd2c78371"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-04-20"}],"displaytype":"detail","filename":"Med_A797_result.pdf","filesize":[{"value":"72.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"審査の結果の要旨","objectType":"other","url":"https://kagawa-u.repo.nii.ac.jp/record/9548/files/Med_A797_result.pdf"},"version_id":"7229fe97-74f5-4fe0-8bda-77cbb258cf86"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Metastatic colorectal cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"CAPOXIRI","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Triplet","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Bevacizumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"FOLFOXIRI","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer : Safety lead‐in results from the QUATTRO-II study","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer : Safety lead‐in results from the QUATTRO-II study","subitem_title_language":"en"}]},"item_type_id":"10006","owner":"11","path":["40"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-04-20"},"publish_date":"2022-04-20","publish_status":"0","recid":"9548","relation_version_is_last":true,"title":["Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer : Safety lead‐in results from the QUATTRO-II study"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-10-16T02:31:23.309293+00:00"}